Jacobs Levy Equity Management
FATE icon

Jacobs Levy Equity Management’s Fate Therapeutics FATE Stock Holding History

Jacobs Levy Equity Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-814,639
Closed -$1.03M – 970
2025
Q3 		$1.03M Sell
814,639
-399,097
-33% -$430K ﹤0.01% 712
2025
Q2 		$1.36M Sell
1,213,736
-989,587
-45% -$1.15M 0.01% 696
2025
Q1 		$1.74M Buy
2,203,323
+616,336
+39% +$755K 0.01% 691
2024
Q4 		$2.62M Sell
1,586,987
-913
-0.1% -$2.3K 0.01% 544
2024
Q3 		$5.56M Sell
1,587,900
-106,317
-6% -$414K 0.02% 427
2024
Q2 		$5.56M Sell
1,694,217
-305,605
-15% -$1.34M 0.02% 437
2024
Q1 		$14.7M Sell
1,999,822
-616,998
-24% -$3.82M 0.07% 243
2023
Q4 		$9.79M Buy
2,616,820
+227,697
+10% +$537K 0.05% 304
2023
Q3 		$5.06M Buy
2,389,123
+54,005
+2% +$179K 0.03% 375
2023
Q2 		$11.1M Buy
2,335,118
+991,489
+74% +$5.47M 0.06% 265
2023
Q1 		$7.66M Buy
+1,343,629
New +$8.11M 0.05% 326
2017
Q4 		– Sell
-16,300
Closed -$65K – 1010
2017
Q3 		$65K Sell
16,300
-33,704
-67% -$115K ﹤0.01% 926
2017
Q2 		$162K Sell
50,004
-10,700
-18% -$41K ﹤0.01% 865
2017
Q1 		$276K Sell
60,704
-33,278
-35% -$122K 0.01% 739
2016
Q4 		$236K Sell
93,982
-30,490
-24% -$81.6K ﹤0.01% 808
2016
Q3 		$388K Sell
124,472
-54,175
-30% -$131K 0.01% 755
2016
Q2 		$304K Sell
178,647
-25,800
-13% -$46.8K 0.01% 879
2016
Q1 		$368K Buy
204,447
+167,194
+449% +$344K 0.01% 814
2015
Q4 		$126K Buy
+37,253
New +$157K ﹤0.01% 728

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jacobs Levy Equity Management's FATE Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 814,639 shares — an estimated $1.03M sold.

Jacobs Levy Equity Management first reported a position in FATE in Q4 2015 and held it in 19 quarters. The position peaked at $14.7M in Q1 2024. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

  • Jacobs Levy Equity Management reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 814,639 Fate Therapeutics shares in Q4 2025, an estimated $1.03M.
  • Jacobs Levy Equity Management first reported a position in Fate Therapeutics in Q4 2015 and held it in 19 quarters.
  • Jacobs Levy Equity Management's Fate Therapeutics position peaked at $14.7M in Q1 2024.
  • 146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.